Inovio Shares Rise On Positive Data For Coronavirus Vaccine Candidate That's Stable At Room Temps

Inovio Pharmaceuticals Inc (NASDAQ: INO) stocks traded higher Thursday after the company released positive Phase 1 data for its COVID-19 DNA vaccine candidate.
What happened: On Wednesday, Inovio published a paper with phase 1 data on INO-4800 that was found to be immunogenic in all test subjects.
Scroll to continue with the content
display
Microsoft and Redis
Meet the fast and fully managed in-memory data store.
Don't miss the opportunity to hear the unique perspectives from Microsoft and partner specialists and learn more about Azure Cache for Redis.
LEARN MORE
In addition, Phase 1 testing identified no major safety adverse events and only six Grade I adverse events, most of which were minor injection site reactions.
Related Link: Why A COVID-19 Vaccine Makes General Electric Stock "More Investable"
Why It Matters: Inovio's INO-4800 coronavirus vaccine candidate didn't come close to winning the market race with vaccines from Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) already approved by the FDA.
However, Moderna's vaccine must be stored and transported at temperatures of minus 20 degrees Celsius, and Pfizer's vaccine must be stored and transported at temperatures of minus 70 degrees Celsius, colder than winter temperatures in Antarctica.
INO-4800, however, is stable for more than a year at room temperature. Nor does it need to be frozen while the van is in storage, potentially making distribution faster and less expensive.
Inovio stocks are up 205% since the start of the year but are down 53.3% over the past six months as competing vaccine candidates seem to have been ahead in the race against the pandemic.
Petrol gas discontinuation: Provided it's as effective and safe as competing vaccines, Inovio's candidate could ultimately be the standard carrier for COVID-19 and future coronavirus vaccine variants.
Analysts have estimated the global COVID-19 vaccine market could be worth $ 10 billion annually. So it's understandable why Inovio investors are excited given the $ 1.7 billion market cap.
See more from Benzinga
Click here for Benzinga option trades
10 tips to add positivity to your trading day (and your life)
Nikola Options Traders Respond to Canceled Republic Services Deal
© 2020 Benzinga.com. Benzinga does not offer investment advice. All rights reserved.
In this article
IN O
+ 1.89%

You should check here to buy the best price guaranteed products.

Last News

Ore Billionaire Sets Sights on Reviving Congo’s Hydro Vision

Mom confesses the ‘petty’ lies she tells her kids: ‘It just makes everything so much easier’

Manifest Cancelled After 3 Seasons

Scheana Shay & Boyfriend Brock Had the Sexiest "Mom & Dad Night Out" Style

Michael Costello Says Alleged Bullying By Chrissy Teigen Led To Suicidal Thoughts: 'I May Never Be OK'

Stolen Army assault rifles keep showing up in California